Multiple Myeloma and Infections: Characterizing the Risks
Despite newer agents being available to patients with multiple myeloma, the rate of infections in this patient population has remained relatively unchanged.
Hematologic Cancer
HEMATOLOGIC CANCER ADVISOR
FEATURED CONTENT
-
-
BMT Societies Issue Recommendations on Posttransplant Maintenance in HL/NHL
Use of maintenance therapy as a therapeutic strategy in posttransplant patients with HL and NHL is increasing in frequency -
Predicting PD-1/PD-L1 Immunotherapy Responses
Finding biomarkers that can broadly and reliably predict immunotherapy outcomes for patients with cancer remains an elusive “holy grail,” said Dr Ott. -
Myeloma Trial Aims to Use Genetic Profile for Treatment Optimization
To improve options for patients with refractory disease, researchers seek to bolster data behind genetic profiling as a way to guide the selection of treatment. -
Treatment of Early FL More Effective With PET-Staging and Contemporary RT
Treatment of stage I/II follicular lymphoma (as determined by FDG-PET parameters) resulted in better freedom from progression and OS rates compared with historical numbers.
HEMATOLOGIC CANCER NEWS
Marginal Zone Lymphoma Presentation at Multiple Mucosal Sites May Be Linked to Poorer Outcomes
Managing Neutropenic Sepsis in Patients With Cancer
Molecular Characterization of Pediatric Follicular Lymphoma
MEK Inhibition Spurs Durable Responses in Patients With Histiocytic Neoplasms
Sustained Efficacy and Safety of Ibrutinib in Relapsed/Refractory CLL
MORE HEMATOLOGIC CANCER INFORMATION
A 47-Year-Old Woman with Pancytopenia After Treatment with Radioiodine Therapy
DARZALEX (daratumumab) for Multiple Myeloma
ZOLINZA (vorinostat) for Cutaneous T-cell Lymphoma
NINLARO (ixazomib) for Multiple Myeloma
GAZYVA (obinutuzumab) for Follicular Lymphoma
VENCLEXTA (venetoclax) for Chronic Lymphocytic Leukemia
EMPLICITI (elotuzumab) for Multiple Myeloma
SPRYCEL (dasatinib) for Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia
Want to read more?
Please login or register first to view this content.
Next post in Hematologic Cancers
